Regional differences in homovanillic acid concentrations after acute and chronic administration of antipsychotic drugs.
D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D001569:Benzodiazepines; D001923:Brain Chemistry / Q000187:drug effects*; D002421:Caudate Nucleus / Q000032:analysis; D002746:Chlorpromazine / Q000494:pharmacology; D003984:Dibenzazepines / Q000494:pharmacology; D005476:Fluphenazine / Q000494:pharmacology; D006719:Homovanillic Acid / Q000032:analysis*; D007031:Hypothalamus / Q000032:analysis; D008032:Limbic System / Q000032:analysis; D008297:Male; D010648:Phenylacetates / Q000032:analysis*; D010879:Piperazines / Q000494:pharmacology; D011817:Rabbits; D013881:Thioridazine / Q000494:pharmacology; D013997:Time Factors
D014151:Anti-Anxiety Agents; D003984:Dibenzazepines; D010648:Phenylacetates; D010879:Piperazines; D001569:Benzodiazepines; D013881:Thioridazine; D005476:Fluphenazine; D002746:Chlorpromazine; D006719:Homovanillic Acid